Collectively, our findings provide critical insights into the glycosylation-dependent mechanisms regulating melanoma progression and highlight the protective role of GCNT2/I-branching in mitigating Gal-3-mediated aggressive disease. The gene discussed is GCNT2; the disease is melanoma.